A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Clinical trial NCT01038804 · COMPLETED
Trial details
- NCT number
- NCT01038804
- Sponsor
- Astellas Pharma Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-01
- Primary completion
- 2012-06-01
- Enrollment
- 101
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.